Today, we talk about BIO chief John Crowley’s views on rare disease innovation, and the “aggressive” slashing of personnel at federal health agencies. Also, Pfizer changes its DEI approach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback